Abnormal lipids in high-risk patients achieving cholesterol targets: A cross-sectional study of routinely collected UK general practice data

Current Medical Research and Opinion

Volumn 24, Issue 9, 2008, Pages 2551-2560

  Belsey, Jonathan ^a,b   de Lusignan, Simon ^a   Chan, Tom ^a   van Vlymen, Jeremy ^a   Hague, Nigel ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b JB Medical Ltd   (United Kingdom)

Author keywords

Cardiovascular disease; Cerebrovascular disease; Cholesterol; Coronary heart disease; Peripheral vascular disease; Primary care; Secondary prevention

Indexed keywords

ANTILIPEMIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GENERAL PRACTICE; HIGH RISK PATIENT; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PREVALENCE; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

AGED; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; GREAT BRITAIN; HUMANS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 53349144000     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802321964     Document Type: Article

References (45)

1. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8
2. Wood D, Wray R, Poulter N, et al. for JBS2: Joint British Societies Guidelines on prevention of CVD in clinical practice. Heart 2005;91 (Suppl):V1-52
3. Quality and outcomes framework guidance: Summary of Indicators - clinical domain, February 2006. http://www.bma.org.uk/ap.nsf/Content/ qof06~summclinical [Accessed 18/03/08]
4. Clinical and Health Outcomes Knowledge Base. http://www.nchod.nhs.uk/ [Accessed 18/03/08]
5. de Lusignan S, Belsey J, Hague N, et al. Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study. J Public Health (Oxf) 2006; 28:361-9
6. NHS. Connecting for Health: MIQUEST. http://www.connectingforhealth.nhs.uk/systemsandservices/data/miquest [Accessed 18/03/08]
7. van Vlymen J, de Lusignan S. A system of metadata to control the process of query, aggregating, cleaning and analysing large datasets of primary care data. Inform Prim Care 2005;13:281-91
8. van Vlymen J, de Lusignan S, Hague N, et al. Ensuring the quality of aggregated General Practice data: Lessons from the Primary Care Data Quality Programme (PCDQ). Stud Health Technol Inform 2005;116:1010-15
9. Department of Health. Prescription Cost Analysis: England 2006 http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/ prescriptions/prescription-cost-analysis-2006 [Accessed 18/03/08]
10. ISD Scotland. Prescription Cost Analysis for Scotland: Year ending 31 March 2007. http://www.isdscotland.org/isd/files/final_F07.xls [Accessed 18/03/08]
11. Health Solutions Wales. Prescription Cost Analysis Wales 2006. http://www.wales.nhs.uk/sites3/Documents/428/PCA%20Wales%202006.xls [Accessed 18/03/08]
12. Central Services Agency. Prescription Cost Analysis: Northern Ireland 2006. http://www.centralservicesagency.n-i.nhs.uk/files/statistics/file/ PCT%202006.xls [Accessed 18/03/08]
13. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
14. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6
15. Backes JM, Ebson CA, Howard PA. Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag 2005;1:317-31
16. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation CGREACE) Study. Curr Med Res Opin 2004;20:627-37
17. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
18. Superko HR, King S, III. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 2008;117:560-8
19. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-45
20. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-18
21. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81
22. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;1285:1585-91
23. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55
24. HPS-2/THRIVE http://www.ctsu.ox.ac.uk/pressreleases/2006-05-31/ hps2-thrive-press-release [Accessed 18/03/08]
25. AIM-HIGH http://accelerator.axioresearch.com/aim-high/ [Accessed 18/03/ 08]
26. Ginsberg HN, Bonds DE, Lovato LC, et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:56-67i
27. IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs. Simvastatin (Study P04103) http://clinicaltrials.gov/show/NCT00202878 [Accessed 01/07/08]
28. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
29. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
30. Merk & Co Inc. ZOCOR prescribing information. 2008 http://www.merck.com/product/usa/pi-circulars/z/zocor/zocor_pi.pdf [Accessed 25/6/08]
31. Law M, Rudnicka AR. Statin safety: A systematic review. Am J Cardiol 2006;97(Suppl):52-60C
32. Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002;90(Suppl):50-60K
33. Havranek JM, Wolfsen AR, Warnke GA, et al. Monotherapy with ezetimibe causing myopathy. Am J Med 2006;119:285-6
34. Simard C, Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can J Cardiol 2006;22:141-4
35. Weffald LA, Flach LA. Myopathy associated with atorvastatin-ezetimibe combination therapy. Pharmacotherapy 2007;27: 309-11
36. Gharavi AG, Diamond JA, Smith DA, et al. Niacin-induced myopathy. Am J Cardiol 1994;74:841-2
37. Goldstein MR. Nicotinic acid-associated myopathy. Am J Med 1989;87:248
38. Litin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am J Med 1989;86:481-3
39. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41
40. Dujovne C, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7
41. Patel J, Kirby M, Hughes EA. The Lipid Audit: analysis of lipid management in two centres in Britain 2003. Br J Cardiol 2004; 11:214-17
42. Van Ganse E, Laforest L, Burke T, et al. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Clin Ther 2007;29:1671-81
43. Bruckert E, Baccara-Dinet M, McCoy F, et al. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005;21:1927-34
44. de Lusignan S, Hague N, Belsey J, et al. The 'rule of halves' still applies to the management of cholesterol in cardiovascular disease: 2002-2005. Br J Cardiot 2006;13:145-53
45. de Lusignan S. An educational intervention, involving feedback of routinely collected computer data, to improve cardiovascular disease management in UK primary care. Methods Inf Med 2007;46:57-62